Disease · MONDO_0015759
B-cell non-Hodgkin lymphoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. B-cell non-Hodgkin lymphoma. Diseases, record MONDO_0015759. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015759
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- B-cell NHL, B-cell lymphoma, B-cell non Hodgkin's lymphoma, B-cell non-Hodgkins lymphoma, lymphomas non-Hodgkin's B-cell, non-Hodgkin's B-cell lymphoma, non-Hodgkin's lymphoma B-cell
- Open Targets
- Highest stage of its drugs
- Approval, for 4 of its 151 drugs, from EMA Human Drugs, FDA and PMDA
- Open Targets
Drugs151
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LONCASTUXIMAB TESIRINE | CHEMBL4297778 | Antibody drug conjugate | Approval | EMA Human Drugs and FDA | 5 | 2 | 2 | Drugs and targets |
| POLATUZUMAB VEDOTIN | CHEMBL3301582 | Antibody drug conjugate | Approval | EMA Human Drugs | 3 | 2 | 1 | Drugs and targets |
| EPCORITAMAB | CHEMBL4650393 | Antibody | Approval | PMDA | 2 | 1 | 1 | Drugs and targets |
| BENDAMUSTINE HYDROCHLORIDE | CHEMBL1201734 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov and TTD | 44 | 42 | 42 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| IBRUTINIB | CHEMBL1873475 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 7 | 6 | 6 | Drugs and targets |
| ORELABRUTINIB | CHEMBL4650321 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ZANUBRUTINIB | CHEMBL3936761 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 4 | 4 | Drugs and targets |
| ENTECAVIR | CHEMBL5314362 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 151
See all 151 drugsTargets218
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 218
See all 218 targetsTrials138
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Phase 1 | 190 | 2020-03-17 | Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell of Head and Neck, Malignant Melanoma | RITUXIMAB, UTOMILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00057811 | Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma | Phase 2 | 97 | 2014-08-22 | Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Small Noncleaved Cell Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Childhood Small Noncleaved Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Small Noncleaved Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Untreated Childhood Acute Lymphoblastic Leukemia | CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, FILGRASTIM, LEUCOVORIN CALCIUM, METHOTREXATE, METHYLPREDNISOLONE, RASBURICASE, RITUXIMAB, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00290498 | Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger | Phase 2 | 67 | 2020-06-02 | Lymphoma | CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PREDNISONE, RITUXIMAB, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT03397706 | Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies | Phase 1/2 | 64 | 2025-03-20 | Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders | NANATINOSTAT, VALGANCICLOVIR | Its record names the disease | ClinicalTrials.gov |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | Phase 2 | 63 | 2017-05-22 | B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00467961 | Stem Cell Transplantation for Patients With Cancers of the Blood | Phase 2 | 61 | 2015-01-06 | CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), AML (Acute Myelogenous Leukemia), Acute Lymphocytic Leukemia, MDS (Myelodysplastic Syndrome) | CYCLOPHOSPHAMIDE, CYCLOSPORINE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT01665768 | Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma | Phase 2 | 56 | 2018-12-26 | CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL), Transformed Lymphoma/DLBCL/PMBCL, Hodgkin's Disease, Gray Zone Lymphoma | EVEROLIMUS, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03038672 | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | Phase 2 | 54 | 2024-10-16 | ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | NIVOLUMAB, VARLILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00054665 | PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma | Phase 2 | 50 | 2012-09-11 | B-Cell Lymphoma | BORTEZOMIB, CYCLOPHOSPHAMIDE, ETOPOSIDE, FILGRASTIM, PREDNISONE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00389818 | Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma | Phase 2 | 43 | 2012-06-29 | Lymphoma | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISONE, RITUXIMAB, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 138
See all 138 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.) vs Group C (Chemotherapy, Monoclonal Antibody Therapy): serious adverse events | 2 of 46 | 6 of 42 | 88 | NCT00057811 | Trial comparisons |
| Part A: PS-341 Alone vs Part B: PS-341 & EPOCH: serious adverse events | 21 of 24 | 40 of 44 | 68 | NCT00054665 | Trial comparisons |
| Part A: PS-341 Alone vs Part B: PS-341 & EPOCH: Number of Participants With Adverse Events | 23 of 23 | 44 of 44 | 67 | NCT00054665 | Trial comparisons |
| R-HCVAD/MA vs R-CHOP: Progression Free Survival (Rate) | 35 of 49 | 7 of 10 | 59 | NCT00290498 | Trial comparisons |
| RHCVAD vs RCHOP: deaths from any cause | 4 of 49 | 0 of 10 | 59 | NCT00290498 | Trial comparisons |
| RHCVAD vs RCHOP: serious adverse events | 49 of 49 | 7 of 10 | 59 | NCT00290498 | Trial comparisons |
| Phase I: Induction vs Phase II: Maintenance: serious adverse events | 3 of 19 | 1 of 29 | 48 | NCT00634179 | Trial comparisons |
| Fenretinide and Rituximab (Rituximab Naive) vs Fenretinide and Rituximab (Rituximab Pre Treated): Response Rates of B-Non-Hodgkin Lymphoma to the Combination of Rituximab and Fenretinide (Phase II) | 4 of 7 | 0 of 16 | 23 | NCT00288067 | Trial comparisons |
| MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg vs MEDI-551 12 mg/kg and MEDI0680 10 mg/kg: Number of Participants With Positive Anti-Drug Antibodies (ADA) for MEDI-551 and MEDI0680 | 1 of 5 | 0 of 5 | 10 | NCT02271945 | Trial comparisons |
| MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg vs MEDI-551 12 mg/kg and MEDI0680 10 mg/kg: deaths from any cause | 3 of 5 | 3 of 5 | 10 | NCT02271945 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials49
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015759
GET https://conductscience.org/api/diseases/v1/MONDO_0015759/drugs?page=2